Company Profile
Allarity Therapeutics Stock Price, News & Catalysts
- Ticker:
- ALLR
- Exchange:
- NASDAQ
- Sector:
- Biopharma
- Location:
- Denmark
Stock performance
1.34 USD (-2.19%)
Close
Last updated: August 17, 2026
26.9M USD
Market cap
Why the stock is moving
The latest company update was “Allarity Therapeutics Reports Second Quarter 2026 Results and Completion of the Phase 3-Ready Stenoparib Manufacturing Campaign”. ALLR changed 0.74% and closed at $1.37 on Aug 14, 2026, indicating a relatively limited closing-price reaction to this clinical readout update.
Company overview
Biomarker-Guided Oncology
Allarity Therapeutics develops personalized cancer therapies paired with drug-specific companion diagnostics. Its strategy is to identify patients whose tumor gene-expression profiles indicate a higher probability of responding to a particular anticancer medicine.
Stenoparib
Stenoparib is an oral small molecule that inhibits PARP1/2 and tankyrase1/2. This dual mechanism combines DNA-damage interference with inhibition of WNT/beta-catenin signaling, a pathway associated with tumor progression, metastasis, and drug resistance. Allarity holds exclusive global development and commercialization rights to the candidate.
DRP Companion Diagnostic
The Drug Response Predictor platform analyzes messenger-RNA expression patterns from tumor biopsies to generate a drug-specific response score. Allarity is developing a stenoparib-specific DRP companion diagnostic to enrich clinical studies for patients most likely to benefit and operates a CLIA-certified laboratory capable of performing the testing for US trials.
Ovarian-Cancer Development
Stenoparib is being evaluated in a Phase 2 study for advanced recurrent ovarian cancer that is platinum-resistant or platinum-ineligible. The program has FDA Fast Track designation, and the completed late-stage manufacturing campaign provides drug supply suitable for a future registrational trial.
Additional Tumor Programs
A Department of Veterans Affairs-funded Phase 2 study is evaluating stenoparib with temozolomide in relapsed small-cell lung cancer. Preclinical findings also support potential development in colorectal cancer through inhibition of WNT pathway signaling.
Future catalysts
Recent news
- 01
- 02
- 03
- 04
- 05
Similar stocks
Peer names with similar commercial maturity, therapeutic overlap, or catalyst patterns.
Frequently Asked Questions
What is the current stock price of Allarity Therapeutics (ALLR)?
Allarity Therapeutics (ALLR) most recently closed at 1.34 USD, a -2.19% move versus the previous session.
What is the market cap of Allarity Therapeutics (ALLR)?
Allarity Therapeutics currently has a market capitalization of 26.9M USD on BioPharmSignal.
What does Allarity Therapeutics do?
Biomarker-Guided Oncology Allarity Therapeutics develops personalized cancer therapies paired with drug-specific companion diagnostics. Its strategy is to identify patients whose tumor gene-expression profiles indicate a higher probability of responding to a particular anticancer medicine. Stenoparib Stenoparib is an oral small molecule that inhibits...
On which exchange is ALLR stock listed?
Allarity Therapeutics (ALLR) is associated with NASDAQ, Denmark, Biopharma.
What is stenoparib?
Stenoparib Stenoparib is an oral small molecule that inhibits PARP1/2 and tankyrase1/2.
Which conditions is Allarity Therapeutics targeting with stenoparib?
Allarity Therapeutics is associated with oncology, cancer therapeutics based on its company overview and current catalyst commentary.
What is Biomarker-Guided?
Biomarker-Guided Oncology Allarity Therapeutics develops personalized cancer therapies paired with drug-specific companion diagnostics.
What is Oncology?
Biomarker-Guided Oncology Allarity Therapeutics develops personalized cancer therapies paired with drug-specific companion diagnostics.